E Vázquez Ruiz de Castroviejo, M del Monte Trujillo Pérez, C Lozano Cabezas, C Avellaneda Molina, M Guzmán Herrera, E Martínez Galiano, H Pousibet Sanfeliú, A Tarabini Castellani, C Pagola Vilardebó, A Alcalá Muñoz
{"title":"抗凝治疗的出血性并发症:预测危险因素分析。","authors":"E Vázquez Ruiz de Castroviejo, M del Monte Trujillo Pérez, C Lozano Cabezas, C Avellaneda Molina, M Guzmán Herrera, E Martínez Galiano, H Pousibet Sanfeliú, A Tarabini Castellani, C Pagola Vilardebó, A Alcalá Muñoz","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Unlabelled: </strong>Anticoagulant therapy has shown its efficacy in the prevention of thromboembolic complications but it is not devoid of bleeding complications. Although the thromboembolic risk of some cardiac diseases may be extrapolated from well-organized clinical trials, the risk of bleeding complications should be determined in the context of the environment in which it is carried out.</p><p><strong>Objective: </strong>To determine the complications of the patients in anticoagulant therapy, in our environment, and to analyse the of risk factors.</p><p><strong>Patients and methods: </strong>We have studied the complications suffered by 300 patients who underwent anticoagulation for cardiac diseases, between March-94 and March-96 retrospectively. We have classified the complications in two groups: a) Fatal or intracranial with sequelae. b) Those requiring hospitalization and/or transfusion. Univariate and multivariant analyses were conducted to identify predictors of complications, including the following factors: age, sex, diabetes, hypertension, length of therapy, distance from our Center to their place of residence, INR (> 3 vs 2 to 3) and number of drugs associated with Acenocoumarol (> or = 3 vs 2 or less).</p><p><strong>Results: </strong>During the follow-up 24 patients died due to non haemorrhagic complications; 3 left the treatment on their cardiologist recommendation; 2 moved their place of residence and 1 was lost in the follow-up. Of 270 remaining 3 (0.55/100 patients-year) had complications of group a and 21 (3.88/100 patients-year) of grub b. INR > 3 and multiple medications were shown as predictors of complications when including some of the complications considered.</p><p><strong>Conclusions: </strong>1) During two years of follow-up 1.1% (0.55/100 patients-year) of patients in anticaogulant therapy had bleeding complications resulting in death or neurological sequelae. 2) When including some of the complications considered the percentage rises to 4.44/100 patients-years. 3) Although there were no differences statistically significant, INR > 3 and polymedication have been found as predictors risk factor. 4) Patients with INR of 2 to 3 and non polymedicated presented a low risk of bleeding complications (1.66/100 patients-year).</p>","PeriodicalId":76513,"journal":{"name":"Sangre","volume":"44 3","pages":"216-21"},"PeriodicalIF":0.0000,"publicationDate":"1999-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Hemorrhagic complications from anticoagulant treatment: analysis of predictive risk factors].\",\"authors\":\"E Vázquez Ruiz de Castroviejo, M del Monte Trujillo Pérez, C Lozano Cabezas, C Avellaneda Molina, M Guzmán Herrera, E Martínez Galiano, H Pousibet Sanfeliú, A Tarabini Castellani, C Pagola Vilardebó, A Alcalá Muñoz\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Unlabelled: </strong>Anticoagulant therapy has shown its efficacy in the prevention of thromboembolic complications but it is not devoid of bleeding complications. Although the thromboembolic risk of some cardiac diseases may be extrapolated from well-organized clinical trials, the risk of bleeding complications should be determined in the context of the environment in which it is carried out.</p><p><strong>Objective: </strong>To determine the complications of the patients in anticoagulant therapy, in our environment, and to analyse the of risk factors.</p><p><strong>Patients and methods: </strong>We have studied the complications suffered by 300 patients who underwent anticoagulation for cardiac diseases, between March-94 and March-96 retrospectively. We have classified the complications in two groups: a) Fatal or intracranial with sequelae. b) Those requiring hospitalization and/or transfusion. Univariate and multivariant analyses were conducted to identify predictors of complications, including the following factors: age, sex, diabetes, hypertension, length of therapy, distance from our Center to their place of residence, INR (> 3 vs 2 to 3) and number of drugs associated with Acenocoumarol (> or = 3 vs 2 or less).</p><p><strong>Results: </strong>During the follow-up 24 patients died due to non haemorrhagic complications; 3 left the treatment on their cardiologist recommendation; 2 moved their place of residence and 1 was lost in the follow-up. Of 270 remaining 3 (0.55/100 patients-year) had complications of group a and 21 (3.88/100 patients-year) of grub b. INR > 3 and multiple medications were shown as predictors of complications when including some of the complications considered.</p><p><strong>Conclusions: </strong>1) During two years of follow-up 1.1% (0.55/100 patients-year) of patients in anticaogulant therapy had bleeding complications resulting in death or neurological sequelae. 2) When including some of the complications considered the percentage rises to 4.44/100 patients-years. 3) Although there were no differences statistically significant, INR > 3 and polymedication have been found as predictors risk factor. 4) Patients with INR of 2 to 3 and non polymedicated presented a low risk of bleeding complications (1.66/100 patients-year).</p>\",\"PeriodicalId\":76513,\"journal\":{\"name\":\"Sangre\",\"volume\":\"44 3\",\"pages\":\"216-21\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sangre\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sangre","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
未标记:抗凝治疗已显示其预防血栓栓塞并发症的功效,但它并非没有出血并发症。虽然一些心脏疾病的血栓栓塞风险可以从组织良好的临床试验中推断出来,但出血并发症的风险应该在进行试验的环境背景下确定。目的:了解环境下抗凝治疗患者并发症的发生情况,并分析其危险因素。患者与方法:回顾性分析了1994年3月至1996年3月间300例因心脏疾病行抗凝治疗的患者的并发症。我们将并发症分为两组:a)致死性或颅内伴后遗症。b)需要住院和(或)输血的患者。进行单变量和多变量分析以确定并发症的预测因素,包括以下因素:年龄、性别、糖尿病、高血压、治疗时间、离我们中心的距离、INR (> 3 vs 2 ~ 3)和与阿塞诺库马洛相关的药物数量(>或= 3 vs 2或更少)。结果:随访中24例患者死于非出血性并发症;3人按照心脏病专家的建议接受治疗;2人迁居,1人在随访中失踪。270例患者中有3例(0.55/100例患者-年)出现a组并发症,21例(3.88/100例患者-年)出现b组并发症。当考虑到一些并发症时,INR > 3和多种药物治疗被认为是并发症的预测因素。结论:1)2年随访期间,1.1%(0.55/100例患者-年)的抗凝治疗患者出现出血并发症导致死亡或神经系统后遗症。2)当考虑到一些并发症时,这一比例上升到4.44/100患者-年。3)虽无统计学差异,但INR > 3和多药治疗可作为预测危险因素。4) INR为2 ~ 3且未多药的患者出血并发症风险较低(1.66/100患者-年)。
[Hemorrhagic complications from anticoagulant treatment: analysis of predictive risk factors].
Unlabelled: Anticoagulant therapy has shown its efficacy in the prevention of thromboembolic complications but it is not devoid of bleeding complications. Although the thromboembolic risk of some cardiac diseases may be extrapolated from well-organized clinical trials, the risk of bleeding complications should be determined in the context of the environment in which it is carried out.
Objective: To determine the complications of the patients in anticoagulant therapy, in our environment, and to analyse the of risk factors.
Patients and methods: We have studied the complications suffered by 300 patients who underwent anticoagulation for cardiac diseases, between March-94 and March-96 retrospectively. We have classified the complications in two groups: a) Fatal or intracranial with sequelae. b) Those requiring hospitalization and/or transfusion. Univariate and multivariant analyses were conducted to identify predictors of complications, including the following factors: age, sex, diabetes, hypertension, length of therapy, distance from our Center to their place of residence, INR (> 3 vs 2 to 3) and number of drugs associated with Acenocoumarol (> or = 3 vs 2 or less).
Results: During the follow-up 24 patients died due to non haemorrhagic complications; 3 left the treatment on their cardiologist recommendation; 2 moved their place of residence and 1 was lost in the follow-up. Of 270 remaining 3 (0.55/100 patients-year) had complications of group a and 21 (3.88/100 patients-year) of grub b. INR > 3 and multiple medications were shown as predictors of complications when including some of the complications considered.
Conclusions: 1) During two years of follow-up 1.1% (0.55/100 patients-year) of patients in anticaogulant therapy had bleeding complications resulting in death or neurological sequelae. 2) When including some of the complications considered the percentage rises to 4.44/100 patients-years. 3) Although there were no differences statistically significant, INR > 3 and polymedication have been found as predictors risk factor. 4) Patients with INR of 2 to 3 and non polymedicated presented a low risk of bleeding complications (1.66/100 patients-year).